Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $326,509.26 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Intellia Therapeutics Price Performance

Shares of NTLA stock traded down $0.33 on Tuesday, reaching $12.47. 2,355,020 shares of the company were exchanged, compared to its average volume of 2,637,028. The company has a 50-day moving average of $14.01 and a 200-day moving average of $19.28. Intellia Therapeutics, Inc. has a one year low of $11.34 and a one year high of $34.87. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -2.29 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The business's quarterly revenue was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.38) EPS. As a group, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wells Fargo & Company lowered their target price on Intellia Therapeutics from $80.00 to $70.00 and set an "overweight" rating for the company in a report on Monday, November 18th. Wedbush reissued a "neutral" rating and set a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. The Goldman Sachs Group cut their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. Finally, Robert W. Baird reduced their target price on Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $54.94.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 5.7% in the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock valued at $251,849,000 after purchasing an additional 659,651 shares during the last quarter. State Street Corp increased its holdings in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock valued at $48,164,000 after purchasing an additional 49,367 shares during the period. FMR LLC boosted its holdings in shares of Intellia Therapeutics by 5.0% in the third quarter. FMR LLC now owns 2,339,522 shares of the company's stock worth $48,077,000 after acquiring an additional 111,104 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Intellia Therapeutics by 19.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock valued at $51,494,000 after buying an additional 371,189 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.